Log in
NASDAQ:ZSAN

Zosano Pharma Stock Forecast, Price & News

$1.62
+0.02 (+1.25 %)
(As of 09/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.58
Now: $1.62
$1.65
50-Day Range
$1.36
MA: $1.61
$1.82
52-Week Range
$0.41
Now: $1.62
$2.45
Volume4.44 million shs
Average Volume3.39 million shs
Market Capitalization$111.10 million
P/E RatioN/A
Dividend YieldN/A
Beta3.19
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Read More
Zosano Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZSAN
CUSIPN/A
Phone510-745-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.40 per share

Profitability

Net Income$-37,590,000.00

Miscellaneous

Employees53
Market Cap$111.10 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$1.62
+0.02 (+1.25 %)
(As of 09/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZSAN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZSAN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zosano Pharma (NASDAQ:ZSAN) Frequently Asked Questions

How has Zosano Pharma's stock been impacted by COVID-19?

Zosano Pharma's stock was trading at $0.5662 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZSAN shares have increased by 186.1% and is now trading at $1.62.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Zosano Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zosano Pharma
.

When is Zosano Pharma's next earnings date?

Zosano Pharma is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Zosano Pharma
.

How were Zosano Pharma's earnings last quarter?

Zosano Pharma Corp (NASDAQ:ZSAN) posted its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.14).
View Zosano Pharma's earnings history
.

When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?

Zosano Pharma shares reverse split on the morning of Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for ZSAN?

4 brokerages have issued 1-year price objectives for Zosano Pharma's shares. Their forecasts range from $2.00 to $7.00. On average, they anticipate Zosano Pharma's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 193.2% from the stock's current price.
View analysts' price targets for Zosano Pharma
.

Are investors shorting Zosano Pharma?

Zosano Pharma saw a increase in short interest in September. As of September 15th, there was short interest totaling 6,820,000 shares, an increase of 26.5% from the August 31st total of 5,390,000 shares. Based on an average trading volume of 5,000,000 shares, the short-interest ratio is currently 1.4 days.
View Zosano Pharma's Short Interest
.

Who are some of Zosano Pharma's key competitors?

What other stocks do shareholders of Zosano Pharma own?

Who are Zosano Pharma's key executives?

Zosano Pharma's management team includes the following people:
  • Mr. John P. Walker, Chairman, CEO & Pres (Age 70)
  • Ms. Hayley Lewis, Sr. VP of Operations (Age 43)
  • Dr. Donald J. Kellerman, VP of Clinical Devel. & Medical Affairs (Age 64)
  • Mr. Greg Kitchener, Chief Financial Officer (Age 48)
  • Jeffrey L. Quillen, Sec.

When did Zosano Pharma IPO?

(ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.

What is Zosano Pharma's stock symbol?

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

How do I buy shares of Zosano Pharma?

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zosano Pharma's stock price today?

One share of ZSAN stock can currently be purchased for approximately $1.62.

How big of a company is Zosano Pharma?

Zosano Pharma has a market capitalization of $111.10 million. The biotechnology company earns $-37,590,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Zosano Pharma employs 53 workers across the globe.

What is Zosano Pharma's official website?

The official website for Zosano Pharma is www.zosanopharma.com.

How can I contact Zosano Pharma?

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.